| 引用本文: | 王楠楠,童旭,孙阜圣,张永健.DHRS9在卵巢浆液性癌中的表达特征及其潜在生物学作用分析[J].中国临床新医学,0,():-. |
| wangnannan,tongxu,sunfusheng.DHRS9在卵巢浆液性癌中的表达特征及其潜在生物学作用分析[J].中国临床新医学,0,():-. |
|
| 摘要: |
| 目的：探讨DHRS9（dehydrogenase/reductase member 9）在卵巢浆液性癌（serous ovarian carcinoma，SOC）中的表达特征及潜在生物学功能，分析其与患者预后、细胞增殖、侵袭、迁移及药物敏感性的关系，为SOC的诊断和个体化治疗提供理论依据。
方法：采用生物信息学分析DHRS9在SOC中的表达及其与临床特征、预后的关系；通过GO（Gene Ontology Enrichment Analysis）和KEGG（Kyoto Encyclopedia of Genes and Genomes）通路富集分析预测其参与的生物学过程和信号通路；基于GDSC（Genomics of Drug Sensitivity in Cancer）数据库预测DHRS9相关药物敏感性；采用卵巢癌细胞系（OVCAR-3和SK-OV-3）进行DHRS9敲低实验，检测细胞增殖、侵袭及迁移能力。
结果：DHRS9在SOC中高表达，并与较差预后显著相关（P＜0.05），差异有统计学意义。GO和KEGG分析显示，DHRS9可能参与细胞增殖、迁移及免疫相关通路。DHRS9高表达组对紫杉醇、顺铂及吉西他滨的IC50值低于低表达组。DHRS9敲低显著抑制OVCAR-3和SK-OV-3细胞的增殖、迁移和侵袭能力。
结论：DHRS9在SOC中高表达且与患者预后密切相关，可能通过调控细胞增殖、迁移及侵袭促进SOC发生发展。DHRS9有望成为预测抗肿瘤药物疗效的潜在生物学标志物，并为SOC治疗靶点的开发提供理论依据。 |
| 关键词: DHRS9 卵巢浆液性癌 细胞增殖与迁移 药物敏感性 |
| DOI： |
| 分类号: |
| 基金项目:黑龙江省自然科学基金项目（编号：YQ2025H001） |
|
| Expression characteristics and potential biological role analysis of dhrs9 in ovarian serous carcinoma. |
|
wangnannan, tongxu, sunfusheng
|
|
The Sixth Affiliated Hospital of Harbin Medical University
|
| Abstract: |
| Objective:To investigate the expression characteristics and potential biological functions of DHRS9 (dehydrogenase/reductase member 9) in serous ovarian carcinoma (SOC), and to analyze its association with patient prognosis, cell proliferation, invasion, migration, and drug sensitivity, thereby providing a theoretical basis for the diagnosis and individualized treatment of SOC.
Methods: Bioinformatics analysis was performed to evaluate the expression of DHRS9 in SOC and its association with clinicopathological characteristics and prognosis. Gene Ontology (GO) Enrichment Analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were conducted to explore the biological processes and signaling pathways associated with DHRS9. Drug sensitivity was predicted using the Genomics of Drug Sensitivity in Cancer (GDSC) database. In vitro, DHRS9 knockdown was performed in ovarian cancer cell lines (OVCAR-3 and SK-OV-3), and its effects on cell proliferation, invasion, and migration were evaluated.
Results: DHRS9 was highly expressed in SOC and was significantly associated with poor prognosis (P < 0.05). GO and KEGG analyses indicated that DHRS9 may be involved in the regulation of cell proliferation, migration, and immune-related pathways. The DHRS9 high-expression group exhibited lower IC50 values for paclitaxel, cisplatin, and gemcitabine than the low-expression group. Furthermore, DHRS9 knockdown significantly inhibited the proliferation, migration, and invasion of OVCAR-3 and SK-OV-3 cells.
Conclusion: DHRS9 is highly expressed in SOC and is closely associated with patient prognosis. It may promote the development and progression of SOC by regulating cell proliferation, migration, and invasion. DHRS9 has the potential to serve as a predictive biomarker for the efficacy of antitumor chemotherapy and may represent a promising therapeutic target for SOC. |
| Key words: DHRS9 Serous ovarian carcinoma Cell proliferation and migration Drug sensitivity |
